Login / Signup

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.

Diamant ThaҫiAndrea BauerRalph von KiedrowskiFlorian SchenckKonstantin ErtnerSophie MöllerAnja FaitMike BastianMatthias Augustin
Published in: Dermatology and therapy (2022)
Patients with moderate-to-severe AD present a long medical history, impaired quality of life, and high prevalence of co-existing type 2 inflammatory diseases. Dupilumab was used as a first-line systemic treatment in 38.6% of patients.
Keyphrases
  • atopic dermatitis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • healthcare
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • oxidative stress
  • chronic pain